生命科学资讯

PepGen hit with partial clinical hold, analysts blame 'understaffed FDA'

Guardant hits the road with colon cancer blood test

Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Nvidia dives deeper into medtech, cancer research with Droplet Biosciences

ARPA-H launches $158M effort to aid first-ever lymphatic system medicines

Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option

UK invests $64M to expand clinical trial access to underserved communities

Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons

Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug

Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

Biohaven reduces scope of R&D cutbacks as pipeline progresses

MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug